Table 5.
Characteristics | ≤57 | ≥57 | P value |
---|---|---|---|
Gender | |||
Female | 88 (51.8%) | 68 (42.5%) | 0.05 |
Male | 82 (48.2%) | 92 (57.5%) | |
Tumor site | |||
Right colon | 47 (27.6%) | 29 (18.1%) | 0.02 |
Left colon | 123 (72.4%) | 131 (81.9%) | |
Histologic subtype | |||
Adenocarcinoma | 138 (81.2%) | 140 (87.5%) | 0.07 |
Mucinous adenocarcinoma | 15 (8.8%) | 14 (8.8%) | |
Others | 17 (10.0%) | 6 (3.8%) | |
Histologic grade | |||
Well | 88 (52.1%) | 85 (53.1%) | 0.05 |
Moderate | 61 (36.1%) | 67 (41.9%) | |
Poor | 20 (11.8%) | 8 (5.0%) | |
Vascular invasion | |||
Yes | 16 (9.4%) | 23 (14.4%) | 0.1 |
No | 154 (90.6%) | 137 (85.6%) | |
Perineural invasion | |||
Yes | 14 (9.1%) | 13 (9.0%) | 0.5 |
No | 140 (90.9%) | 132 (91.0%) | |
Total lymph node | |||
Mean (SD) | 24.5 (±10.30) | 17.9 (±9.06) | 0.000 |
LN > 12 | 68 (90.7%) | 58 (80.6%) | 0.04 |
LN < 12 | 7 (9.3%) | 14 (19.4%) | |
Family history of cancer | |||
Yes | 9 (5.3%) | 3 (1.9%) | 0.02 |
No | 161 (94.7%) | 157 (98.1%) | |
Tumor stage (T) | |||
T1 | 3 (0.0%) | 1 (0.6%) | 0.4 |
T2 | 22 (13.1%) | 30 (18.8%) | |
T3 | 101 (60.1%) | 97 (60.6%) | |
T4 | 42 (25.0%) | 32 (20.0%) | |
Distant metastases (M) | |||
M0 | 134 (79.8%) | 124 (78.5%) | 0.4 |
M1 | 34 (20.2%) | 34 (21.5%) | |
Disease stages | |||
I | 13 (7.6%) | 15 (9.4%) | 0.6 |
II | 80 (47.1%) | 81 (50.6%) | |
III | 42 (24.7%) | 31 (19.4%) | |
IV | 35 (20.6%) | 33 (20.6%) | |
MSI status | |||
MSI | 26 (15.3%) | 11 (6.9%) | 0.01 |
MSS | 144 (84.7%) | 149 (93.1%) | |
RAS mutation | |||
Presence | 16 (46.8%) | 22 (57.9%) | 0.3 |
Absence | 36 (42.1%) | 41 (53.2%) |
SD: standard deviation; LN: lymph node; MSI: microsatellite instability; MSS: microsatellite stable.